Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.15.1 (ACE)
 18,300 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of chlorophenothane (pp'--DDT) and five structurally related compounds op-DDD (op'-DDD, pp'-DDD, DTE, DCMP and DCP see text) on the cerebral hemisphere gamma-aminobutyric acid (GABA), the main inhibitory transmitter in brain contents and possible correlation with central activities was demonstrated in rats. The tested compounds were given in oral doses of 600 mg/kg in peanut oil. Cerebral GABA content was determined 1, 3 and 6 hrs after the ingestion of pp'-DDT and 3 hrs after each of the other drugs. The mean GABA content in each group of rats was compared with control groups, either without any treatment, or receiving the equivalent volume of peanut oil. pp'-DDT produced a significant reduction in brain GABA contents 3 and 6 hrs after its administration. This was accompanied by excitability, tremor and clonic convulsions. Of the congenors, only DTE exerted a similar effect. The present results point to the possibility of partial involvement of GABA in the tremor and convulsions induced by pp'-DDT. They also indicate the importance of the CCl2 grouping in the molecule for the induction of central effects of pp'-DDT.
Pol J Pharmacol Pharm
PMID:Investigation of the effect of chlorophenothane and certain chemically related compounds on the cerebral gamma-aminobutyric acid contents in rats. 74 May 48

Blood serum activity of ACE, alfa2-macroglobulin as well as triglycerides concentration was determined in 90 patients with diabetes and in 40 healthy persons. Taking into account criteria established by WHO the patients with diabetes were divided into two groups. The first group consisted of 32 patients with diabetes of type I (juvenile one); the second group consisted of 58 patients with diabetes of type II (adult one). It was found that blood serum level of all tested parameters is statistically increased (p < or = 0.001) in comparison with control group. In patients with diabetes of type I the level of alfa2-macroglobulin and ACE was higher than in those with diabetes of type II. The serum contents of triglycerides in both groups of patients was comparable. No correlation between parameters determined in patients with diabetes was found.
Mater Med Pol
PMID:Blood serum angiotensin-converting enzyme, alfa2-macroglobulin and triglycerides in patients with diabetes. 128 70

Angiotensin-converting enzyme in the blood serum was assayed with Friedland's and Silverstein's Technique in 24 female patients with untreated hyperthyroidism accompanying Graves-Basedow disease. Mean ACE activity was significantly higher in patients than that in the group of healthy individuals of the same age. Increased ACE activity noted in patients with Graves-Basedow disease may, therefore, indicated a significant role of renin-angiotensin-aldosterone system in the etiopathogenesis of hypertension in this disease.
Pol Tyg Lek
PMID:[Activity of angiotensin-converting enzyme in women with hyperthyroidism accompanying Graves-Basedow disease]. 133 53

The study involved 274 patients, including 240 women, divided into various subgroups, according to the age, body weight, and a phase of menstruation cycle in women, and a subgroup of 34 men. According to the design of the studies, blood serum ACE activity was determined spectrophotometrically with a technique described by Friedland and Silverstein in all patients. The obtained results suggest that blood serum ACE activity does not depend on the sex, age, body weight, and phase of the menstruation cycle in women.
Pol Tyg Lek
PMID:[Does the activity of angiotensin converting enzyme depend on sex, age, body weight and phase of the menstruation cycle in women?]. 133 55

Serum activity of angiotensin converting enzyme (ACE) has been measured in 13 women (mean age 43.1 years) with primary hypothyroidism by spectrofluorometric method of Friedland and Silverstein. The mean enzyme activity was significantly lower in hypothyroid patients than in healthy persons. There is no significant correlation between ACE activity and thyroid hormones concentration.
Endokrynol Pol 1991
PMID:[Activity of angiotensin converting enzyme in women with hypothyroidism]. 136 6

Captopril, an inhibitor of angiotensin converting enzyme is widely used in the treatment of hypertension and congestive heart failure. It contains active sulfhydryl group and shares other structural feature with cysteine, the main substrate of glutathione. Experiments were undertaken to examine the effect of captopril on concentration of endogenous glutathione in the liver and to examine the ability of captopril to protect against paracetamol-induced hepatotoxicity. Single doses of captopril (30 mg/kg) given to male Sprague-Dawley rats produced a significant time dependent depletion of hepatic glutathione: at 3 h--16% (controls--10% as the effect of fasting; p less than 0.02), at 5 h--25% (controls--17%; p less than 0.02). Pretreatment of rats with single doses of captopril (30 mg/kg) 2 hours prior to administration of toxic doses of paracetamol (2500 mg/kg) produced a significant depletion of hepatic glutathione level as compared with animals without pretreatment with captopril (median: 2.95 mumol/g liver and 3.50 mumol/g liver, respectively; p less than 0.01). This was not accompanied by a difference in the hepatotoxic effect of paracetamol as assessed by histological staging of necrosis. Studies on covalent binding of paracetamol showed that neither captopril at the doses 30 mg/kg, nor penicillamine (20 mg/kg) affected covalent binding of paracetamol metabolites to cell protein. The results suggest that captopril despite its structural similarity to cysteine depletes hepatic glutathione level and does not protect against paracetamol hepatotoxicity.
Pol Arch Med Wewn 1992 Jun
PMID:[Effect of captopril on glutathione level in the liver and paracetamol-induced liver damage in rats]. 140 91

The aim of this investigation was to compare inhaled budesonide vs oral prednisone in the maintenance phase treatment of pulmonary sarcoidosis. Double-blind controlled study was performed in 40 patients with stage II or III pulmonary sarcoidosis. After initial systemic 6 weeks treatment with prednisone (40 reduced to 20 mg daily) patients were allocated either to systematically (P) or topically (B) treated group. P patients continued with 10 mg prednisone daily, B patients were given inhaled budesonide 1.6 mg daily. The progress of treatment was assessed by serial radiography, spirometry, serum ACE activity and plasma cortisol levels. All patients completed the 12 months treatment. Using a numerical score to assess changes on the chest radiograms P patients improved by 1.7 +/- 0.66 points; B patients improved by 1.15 +/- 0.81 points. Spirometric changes were insignificant. Serum ACE fell from 107 +/- 51 U/L in the P group and 92 +/- 40 U/L in the B group to 46 +/- 11 U/L and 38 +/- 21 U/L respectively during the initial phase of treatment. In the maintenance phase ACE levels remained lower than initial ones in both groups. Morning cortisol plasma levels studied in 10 patients (5 in each group) decreased significantly during the initial phase. Thereafter cortisol levels remained low in the P patients returning to the lower limit of normal values in the B patients. We conclude that inhaled budesonide may be a safe and effective alternative to oral steroids in the maintenance treatment of pulmonary sarcoidosis especially in the early, stage II, disease.
Pol Arch Med Wewn 1992 Jul
PMID:[Comparison of the effectiveness of budesonide and prednisone in the maintenance treatment of pulmonary sarcoidosis]. 145 57

Two new analogs of captopril were synthesized. Inhibition of angiotensin converting enzyme (ACE) by these compounds in vitro and in vivo was determined using fluorimetric method. The obtained compounds were much weaker ACE inhibitors than captopril.
Pol J Pharmacol Pharm
PMID:Synthesis and antienzymic activity of two new angiotensin converting enzyme inhibitors. 166 47

Captopril, an angiotensin converting enzyme inhibitor, was evaluated for a potential antidepressive activity in several animal models. The drug administered in doses of 3-30 mg/kg ip neither affected the reserpine- or apomorphine-induced hypothermia in mice nor reduced the immobility time in the forces swimming test in mice and rats. Moreover, captopril administered repeatedly (10 mg/kg ip, twice daily for 14 days) neither changed the density or affinity of cortical beta-adrenoceptors nor modified the nomifensine-induced locomotor hyperactivity in rats. These results suggest that captopril has no antidepressant-like activity in animal models.
Pol J Pharmacol Pharm
PMID:Captopril lacks the antidepressant-like activity in animal models. 166 33

The aim of the study was to assess serum ACE (S-ACE) activity in atopic bronchial asthma. S-ACE activity values were determined in 50 subjects (11 blood donors, 39 asthmatics) using the radioenzymatic method with Ventrex Laboratories kits. The authors did not find any differences between asthmatics in clinical remission, not receiving therapy, patients receiving prednisone (mean daily dose 10.0 +/- 2.5 mg) and healthy blood donors. In subjects with exacerbations of bronchospasm (not receiving steroids) S-ACE activity was significantly higher.
Pneumonol Alergol Pol 1991
PMID:[Serum angiotensin converting enzyme (SACE) in patients with atopic bronchial asthma]. 166 46


1 2 3 4 5 6 7 8 9 10 Next >>